Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.
about
New Insights into the Function of the Immunoproteasome in Immune and Nonimmune CellsNew molecular targets in mantle cell lymphomaElucidation of the α-keto-aldehyde binding mechanism: a lead structure motif for proteasome inhibitionThe immunoproteasome and viral infection: a complex regulator of inflammationSelective inhibition of the immunoproteasome by ligand-induced crosslinking of the active siteIndolo-phakellins as β5-specific noncovalent proteasome inhibitorsSelective Inhibition of the Immunoproteasome by Structure-Based Targeting of a Non-catalytic CysteineA clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myelomaTrial Watch: Proteasomal inhibitors for anticancer therapyMolecular mechanisms of bortezomib resistant adenocarcinoma cellsNitric oxide-dependent CYP2B degradation is potentiated by a cytokine-regulated pathway and utilizes the immunoproteasome subunit LMP2Carfilzomib: a novel second-generation proteasome inhibitorCarfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma.Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivoAn open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myelomaAssessing subunit dependency of the Plasmodium proteasome using small molecule inhibitors and active site probesA novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.Nature of pharmacophore influences active site specificity of proteasome inhibitors.Apigenin manipulates the ubiquitin-proteasome system to rescue estrogen receptor-β from degradation and induce apoptosis in prostate cancer cells.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells.Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.Molecular targeted approaches in mantle cell lymphoma.Elucidating the catalytic subunit composition of distinct proteasome subtypes: a crosslinking approach employing bifunctional activity-based probes.Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.Subunit specific inhibitors of proteasomes and their potential for immunomodulationA selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice.Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits.Selective depletion of tumour suppressors Deleted in Colorectal Cancer (DCC) and neogenin by environmental and endogenous serine proteases: linking diet and cancerActivity-based near-infrared fluorescent probe for LMP7: a chemical proteomics tool for the immunoproteasome in living cells.Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit.Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma.A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myelomaThe 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma.The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.
P2860
Q26774372-117F77E0-FAC4-4B17-9B54-D26E03C46BA0Q26821766-A4160957-9EE5-4928-A513-12A7836E7C31Q27666372-81C965D1-EBFC-4E01-BE06-F5D5DB677E0FQ27694656-02A1AAF3-AF31-4ACB-9EE0-9DB6438DDB1DQ27695633-465548E7-4AF2-4FDA-BB80-E1A5515D2F63Q27697335-44164553-C342-469A-91BB-CD24137F20FEQ27702605-D444D347-C1A8-46A2-8AC1-639562D206ADQ28067148-8ACE2EA4-C852-4AE0-B5AD-2FF30A2FE69EQ28082910-EC5FCF31-0D47-4F4A-A7AB-EF5B34EF7702Q28478538-4D05E070-0270-479B-92B4-C1E1E60D154FQ28584243-46756E2B-CD80-4448-B52D-A50A12364C7BQ33395298-931C4811-B84E-4E58-AE36-D52FC23D07FDQ33405119-69CAB2AB-053C-4554-96C6-DBE825645C19Q33416105-B7E8A358-A856-4593-8595-6D2BB4A4E626Q33430690-336E2DEB-DCE9-40B4-AD37-92A471F7E13DQ33742779-BC0CC66F-A2DB-468A-BDD3-48755BA4152CQ33896749-0353DC57-F97A-4D11-8498-6B49B5BFCD7BQ34008600-3E61A703-F548-4D44-988F-EA476F0E7760Q34061291-BD324201-8ACB-4182-9462-CF960E24671DQ34134986-FBD85D23-4CAA-49DF-B93F-04A531DD543EQ34291281-CF3810A2-1C91-42BE-BE31-A1C517A157D2Q34401062-CFFD542B-FB8A-428B-92CD-FBCF66536FB1Q34448480-D459C14B-2C15-45B6-8087-FB07D3CC0A5BQ34773850-722FC87F-9D89-4586-B195-971058BB519EQ34999190-398A4EA5-954C-4D5E-B0F2-0AE2AFC40D1FQ35005087-FA860EB2-5F51-4F81-8844-A8BDA89A2693Q35009005-6E35A7A7-E08A-463C-8892-0784F3D8E97CQ35127368-69EEEBB9-0C70-463E-9850-B27FB9BFF07DQ35555565-3908EC8D-D9CA-4268-A739-B2AC16A41F0BQ35969785-BC85DC04-5E6A-4FDF-9ACF-34E5CA26EDA1Q36042649-EF088D06-4B44-4AA4-858F-20A8F2119258Q36075303-34C557F8-47FD-451A-8C07-5DEAB56AED68Q36150369-C9584DFE-0E25-4367-B55E-A11913FF1455Q36156772-60F43B39-9398-4705-9A68-4DCE650C082EQ36201624-48718083-E692-407F-8258-C622E9A79BEEQ36354644-7A26897F-E10C-40FC-ADA4-A21244B0500AQ36583731-5E8CEB55-9276-4195-A189-C62CCDE06766Q36671445-FF06AA29-77C2-40D9-A895-10772D8EDF75Q36709283-E0053C48-3020-40D9-BC05-A38AE4E7AECFQ36815262-447E39F7-5A91-4B3A-B121-1A4D8655F6C5
P2860
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Carfilzomib can induce tumor c ...... ke activity of the proteasome.
@en
Carfilzomib can induce tumor c ...... ke activity of the proteasome.
@nl
type
label
Carfilzomib can induce tumor c ...... ke activity of the proteasome.
@en
Carfilzomib can induce tumor c ...... ke activity of the proteasome.
@nl
prefLabel
Carfilzomib can induce tumor c ...... ke activity of the proteasome.
@en
Carfilzomib can induce tumor c ...... ke activity of the proteasome.
@nl
P2093
P1433
P1476
Carfilzomib can induce tumor c ...... ke activity of the proteasome.
@en
P2093
Catherine Sylvain
Erika Suzuki
Francesco Parlati
James B Lorens
Kevin D Shenk
Konstantin Levitsky
Mark K Bennett
Monette Aujay
Paulina Ruurs
Susan J Lee
P304
P356
10.1182/BLOOD-2009-05-223677
P407
P577
2009-08-11T00:00:00Z